Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Merck KGaA, Darmstadt, Germany, has entered into an agreement to acquire Bio-Techne in an all-cash deal valued at $11.3 billion.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Merck KGaA agreed to acquire Bio-Techne in an all-cash deal valued at $11.3 billion to expand its presence in life sciences markets. Following the announcement, the story quieted without a definitive conclusion in the provided coverage.
Epilogue added 141d ago, after coverage quieted.
The brief
Merck KGaA, Darmstadt, Germany, is set to acquire the Minneapolis-based life sciences firm Bio-Techne. The transaction is structured as an all-cash purchase, intended to expand the German company’s reach within the life sciences market. This acquisition marks the largest deal for the company since its purchase of Sigma-Aldrich in 2015.
Coverage from outlets including Reuters, The Wall Street Journal, Financial Times, and CBS News highlights the transaction value and the strategic focus on lab-tools and life science sectors. Financial reporting by Yahoo Finance and TradingView notes an increase in Bio-Techne stock, while some analysts at Deutsche Bank have adjusted their ratings for the company following the announcement. Market observers are monitoring the status of the acquisition and its impact on shareholders for both entities.
Future updates will track the progress of the transaction, which is expected to yield synergies of €140 million by the third year. Coverage does not yet specify the expected closing date for the deal.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 141d ago.
Quick answers
What is the total value of the acquisition?
The acquisition is valued at $11.3 billion.
What are the projected financial outcomes of the deal?
The merger is expected to generate €140 million in synergies by the third year.
Is Bio-Techne based in Germany?
No, Bio-Techne is based in Minneapolis.
Coverage (15)
- Bio-Techne (TECH) Soars 20% on Merck $11.3B Merger Yahoo Finance · 144d ago
- Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history Star Tribune · 144d ago
- PR News | Joele Frank Works Bio-Techne's $11.3B Deal O'Dwyer's PR · 144d ago
- Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire · 144d ago
- MRK: $11.3bn all-cash acquisition expands life science reach, with €140m synergies by year 3 TradingView · 144d ago
- Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $66 marketscreener.com · 144d ago
- Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? TradingView · 144d ago
- Merck KGaA throws down $11.3B for Bio-Techne in its biggest deal since 2015 Sigma-Aldrich buy Fierce Pharma · 144d ago
- Bio-Techne Is Today’s Top S&P 500 Stock. Germany’s Merck to Buy Company for $11.3 Billion. Barron's · 144d ago
- Bio-Techne, a Minneapolis life sciences firm with 500,000 products, to be sold to German company for $11.3 billion CBS News · 144d ago
- Germany's Merck boosts life sciences business with $11 billion bet on Bio-Techne Reuters · 144d ago
- German group Merck to buy Bio-Techne in $11.3bn deal Financial Times · 144d ago
- Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal CNBC · 144d ago
- Germany’s Merck to Boost Lab-Tools Business With $11 Billion Bio-Techne Deal WSJ · 144d ago
- Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets PR Newswire · 144d ago
Topics
Related trends
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson has agreed to buy Austin-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease treatments.
Diamondback nears $5 billion deal to buy drilling portfolio from Double Eagle, FT says
Diamondback Energy agreed to buy Double Eagle subsidiaries for about 15.56 million shares and $2.15 billion cash, valuing the deal at roughly $5 billion, with closing expected December 21, 2026.
Gen Z judges colleagues who use AI, but paradoxically may see it as the key to their own promotion
New survey coverage reveals a stark generational paradox as younger workers harbor deep concerns over artificial intelligence while eyeing promotion pathways.
$25,000 county grant aims to keep Twin Trees restaurant on Avery Avenue open
A Syracuse institution reopens after a county grant reverses a permanent closure.
Eric Trump-backed robot soldier startup can't pay staff after founder borrowed $4.6 million from company to buy home
An Eric Trump-backed robot soldier startup misses payroll after its founder reportedly borrows millions for a home.
US Data Centers' Carbon Footprint Rivals Small European Countries
US data centers' carbon footprint now rivals that of small European countries, according to Barron's coverage.